{"id":"clexane-lmwh","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Bleeding"},{"rate":"0.1-1","effect":"Thrombocytopenia"},{"rate":"1-5","effect":"Injection site hematoma"},{"rate":"1-3","effect":"Elevated transaminases"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enoxaparin is derived from unfractionated heparin and works by potentiating antithrombin III, a natural anticoagulant. This results in selective inhibition of coagulation factors Xa and IIa, preventing thrombin generation and fibrin clot formation. It has a more predictable pharmacokinetic profile and longer half-life than unfractionated heparin, allowing for subcutaneous dosing.","oneSentence":"Clexane (enoxaparin) is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:31.710Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboembolism prophylaxis in surgical patients"},{"name":"Treatment of deep vein thrombosis and pulmonary embolism"},{"name":"Acute coronary syndrome"},{"name":"Prevention of clotting in hemodialysis"}]},"trialDetails":[{"nctId":"NCT05672550","phase":"PHASE4","title":"Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06-28","conditions":"Pediatric Kidney Transplant Recipients","enrollment":50},{"nctId":"NCT07464808","phase":"NA","title":"Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-11-28","conditions":"Venous Thromboembolic Event","enrollment":25},{"nctId":"NCT07462182","phase":"NA","title":"Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction","status":"NOT_YET_RECRUITING","sponsor":"Muhammad Aamir Latif","startDate":"2026-04-01","conditions":"Intrauterine Growth Restriction","enrollment":108},{"nctId":"NCT07015905","phase":"PHASE3","title":"REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-06-25","conditions":"Venous Thromboembolism (VTE)","enrollment":2000},{"nctId":"NCT06454630","phase":"PHASE2","title":"A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-06-27","conditions":"Venous Thromboembolism","enrollment":179},{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":"Healthy Participants","enrollment":186},{"nctId":"NCT07140211","phase":"PHASE3","title":"Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis","status":"RECRUITING","sponsor":"Marc Blondon","startDate":"2025-10-15","conditions":"Venous Thromboembolism (VTE), Postpartum","enrollment":9200},{"nctId":"NCT07384598","phase":"NA","title":"Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration.","status":"NOT_YET_RECRUITING","sponsor":"Clinique Saint Pierre Ottignies","startDate":"2026-02-01","conditions":"Thromboprophylaxis, Critical Illness, Intensive Care (ICU)","enrollment":60},{"nctId":"NCT05848713","phase":"PHASE3","title":"AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia","status":"RECRUITING","sponsor":"University of Manitoba","startDate":"2023-10-10","conditions":"Community-acquired Pneumonia","enrollment":4000},{"nctId":"NCT06243510","phase":"NA","title":"Comparison of Apixaban Versus Enoxaparin","status":"ENROLLING_BY_INVITATION","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2023-11-24","conditions":"Bladder Cancer","enrollment":90},{"nctId":"NCT04273607","phase":"PHASE2, PHASE3","title":"Anticoagulation-free VV ECMO for Acute Respiratory Failure","status":"RECRUITING","sponsor":"Damian Ratano","startDate":"2022-09-01","conditions":"Extracorporeal Membrane Oxygenation Complication","enrollment":40},{"nctId":"NCT07124819","phase":"PHASE3","title":"Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin","status":"COMPLETED","sponsor":"Avexima Diol LLC","startDate":"2024-07-22","conditions":"Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Venous Thromboembolism (VTE)","enrollment":215},{"nctId":"NCT07140523","phase":"PHASE2","title":"A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA","status":"RECRUITING","sponsor":"Sirius Therapeutics Co., Ltd.","startDate":"2025-09-16","conditions":"Venous Thromboembolism","enrollment":450},{"nctId":"NCT07330661","phase":"NA","title":"Nursing-Led Deep Vein Thrombosis Prevention in Neurosurgery","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2021-01-01","conditions":"Deep Vein Thrombosis (DVT)","enrollment":1286},{"nctId":"NCT06370273","phase":"PHASE3","title":"Thromboprophylaxis in Lower Limb Immobilisation","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-11-12","conditions":"Thrombosis, Injury Leg","enrollment":10044},{"nctId":"NCT07270263","phase":"NA","title":"Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2024-11-22","conditions":"Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","enrollment":100},{"nctId":"NCT05255003","phase":"PHASE4","title":"STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis","status":"RECRUITING","sponsor":"Tzu-Fei Wang","startDate":"2022-08-29","conditions":"Cancer-associated Thrombosis, Thrombocytopenia","enrollment":50},{"nctId":"NCT07243080","phase":"PHASE4","title":"Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention","status":"RECRUITING","sponsor":"Mayo Hospital Lahore","startDate":"2025-10-10","conditions":"Deep Venous Thromboses, Laparotomy Patients","enrollment":212},{"nctId":"NCT01588171","phase":"NA","title":"Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum","status":"COMPLETED","sponsor":"Hawler Medical University","startDate":"2012-05","conditions":"Venous Thromboembolic Diseases","enrollment":7020},{"nctId":"NCT05203705","phase":"PHASE2","title":"Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty","status":"TERMINATED","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2022-03-07","conditions":"Prevention of Venous Thrombosis After TKA","enrollment":64},{"nctId":"NCT07228663","phase":"PHASE3","title":"Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2025-12-01","conditions":"Hip Fracture Surgery, Cardiovascular Prevention, Venous Thromboembolism (VTE)","enrollment":100},{"nctId":"NCT04861103","phase":"PHASE4","title":"Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2020-10-01","conditions":"Pregnancy, High Risk, Anticoagulants","enrollment":12},{"nctId":"NCT07213713","phase":"","title":"Evaluation of Anti-Xa Activity in Patients With Severe Obesity After Subcutaneous Injection of Enoxaparin for Antithrombotic Prophylaxis at Two Different Sites.","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-10-01","conditions":"Venous Thromboembolism, Obese Patients","enrollment":80},{"nctId":"NCT07189897","phase":"PHASE4","title":"Apixaban or Enoxaparin After Head and Neck Cancer Surgery","status":"RECRUITING","sponsor":"Kiranya Arnold","startDate":"2025-10","conditions":"Venous Thromboembolism, Head and Neck Cancer","enrollment":76},{"nctId":"NCT03244020","phase":"PHASE4","title":"LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology","status":"ENROLLING_BY_INVITATION","sponsor":"Massachusetts General Hospital","startDate":"2018-02-16","conditions":"Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma","enrollment":2868},{"nctId":"NCT06180889","phase":"PHASE2","title":"Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Alphamab Co., Ltd.","startDate":"2023-12-20","conditions":"Knee Arthroplasty, Total","enrollment":241},{"nctId":"NCT07168005","phase":"NA","title":"Informative Video Before LMWH Postpartum - Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Wolfson Medical Center","startDate":"2025-10-15","conditions":"Venous Thromboembolism (VTE), Postpartum Care, Anxiety","enrollment":160},{"nctId":"NCT06517563","phase":"PHASE1","title":"Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin","status":"ACTIVE_NOT_RECRUITING","sponsor":"VarmX B.V.","startDate":"2024-08-14","conditions":"Coagulation Disorder","enrollment":16},{"nctId":"NCT06118957","phase":"PHASE2","title":"Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery","status":"COMPLETED","sponsor":"University of Utah","startDate":"2023-10-11","conditions":"Thromboembolism","enrollment":64},{"nctId":"NCT05618808","phase":"PHASE2","title":"A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-05-24","conditions":"Venous Thromboembolism","enrollment":373},{"nctId":"NCT06913595","phase":"PHASE1","title":"Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2024-03-25","conditions":"Deep Venous Thrombosis","enrollment":100},{"nctId":"NCT07132515","phase":"PHASE4","title":"Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2023-08-15","conditions":"Cirrhosis, HCC - Hepatocellular Carcinoma, Portal Vein Thrombosis","enrollment":100},{"nctId":"NCT04762992","phase":"PHASE3","title":"LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)","status":"ENROLLING_BY_INVITATION","sponsor":"Centro Hospitalar de Lisboa Central","startDate":"2022-07-18","conditions":"Fetal Growth Retardation, Prematurity, Pre-Eclampsia","enrollment":12},{"nctId":"NCT07116239","phase":"NA","title":"Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-09","conditions":"Nephrotic Syndrome, Hypoalbuminemia","enrollment":60},{"nctId":"NCT06004674","phase":"PHASE2","title":"Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project","status":"RECRUITING","sponsor":"Endeavor Health","startDate":"2023-12-26","conditions":"Adverse Pregnancy Outcome","enrollment":20},{"nctId":"NCT06515730","phase":"PHASE4","title":"Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2025-04-08","conditions":"Left Ventricular Thrombus, Acute Myocardial Infarction","enrollment":212},{"nctId":"NCT04504318","phase":"PHASE1, PHASE2","title":"Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT","status":"COMPLETED","sponsor":"Stanford University","startDate":"2020-08-12","conditions":"Venous Thromboembolism","enrollment":82},{"nctId":"NCT04997265","phase":"NA","title":"Strategies for Anticoagulation During Venovenous ECMO","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-05-12","conditions":"Acute Hypoxemic Respiratory Failure, Anticoagulant-induced Bleeding, Thromboembolism","enrollment":26},{"nctId":"NCT04924322","phase":"PHASE2, PHASE3","title":"Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies","status":"RECRUITING","sponsor":"Yale University","startDate":"2022-05-11","conditions":"Deep Venous Thrombosis","enrollment":258},{"nctId":"NCT06868823","phase":"","title":"Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation","status":"RECRUITING","sponsor":"University Hospital, Motol","startDate":"2025-05-01","conditions":"Lung Transplantation, Extracorporeal Membrane Oxygenation (ECMO), Anticoagulants and Bleeding Disorders","enrollment":40},{"nctId":"NCT06845423","phase":"PHASE4","title":"Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2025-05-16","conditions":"Venous Thromboembolism (VTE), Post Partum Women","enrollment":2400},{"nctId":"NCT04536272","phase":"PHASE3","title":"Reduced Anticoagulation Targets in ECLS (RATE)","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2020-10-01","conditions":"Heart Failure, Respiratory Failure, Extracorporeal Membrane Oxygenation","enrollment":330},{"nctId":"NCT05735639","phase":"PHASE4","title":"THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2024-01-22","conditions":"Venous Thromboembolism, Varicose Veins","enrollment":6660},{"nctId":"NCT06689241","phase":"NA","title":"Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2024-10-01","conditions":"Morbid Obesity, Bariatric Surgery Candidate","enrollment":162},{"nctId":"NCT03891524","phase":"PHASE2","title":"A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-06-17","conditions":"Arthroplasty, Replacement, Knee","enrollment":1242},{"nctId":"NCT05895136","phase":"PHASE2","title":"A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).","status":"RECRUITING","sponsor":"European Foundation for Study of Chronic Liver Failure","startDate":"2024-07-01","conditions":"Liver Cirrhosis, Decompensated Cirrhosis of Liver, Acute on Chronic Liver Failure (ACLF)","enrollment":90},{"nctId":"NCT06494878","phase":"PHASE3","title":"The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2025-04","conditions":"Venous Thromboembolism, Postpartum Period, Aspirin","enrollment":8805},{"nctId":"NCT05058924","phase":"NA","title":"Low Molecular Weight hEparin vs. Aspirin Post-partum","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2021-08-29","conditions":"Venous Thromboembolism","enrollment":30},{"nctId":"NCT02798471","phase":"PHASE3","title":"Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2017-03-27","conditions":"Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)","enrollment":290},{"nctId":"NCT06010446","phase":"","title":"Intravenous Continuous LMWH Seems to Be Safe Alternative to UFH in VV ECMO Patients","status":"COMPLETED","sponsor":"University Hospital, Motol","startDate":"2019-05-15","conditions":"Refractory Respiratory Failure","enrollment":43},{"nctId":"NCT05245877","phase":"PHASE4","title":"Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery","status":"RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2022-08-17","conditions":"Pancreas Cancer, Pancreas Neoplasm, Surgery","enrollment":800},{"nctId":"NCT04731558","phase":"PHASE4","title":"Pre- Vs Postoperative Thromboprophylaxis for Liver Resection","status":"RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2021-02-10","conditions":"Liver Cancer, Surgery, Thrombosis, Deep Vein","enrollment":1012},{"nctId":"NCT06818279","phase":"PHASE2, PHASE3","title":"Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-01-31","conditions":"Portal Vein Thrombosis, Liver Cirrhosis","enrollment":120},{"nctId":"NCT04362085","phase":"PHASE3","title":"Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2020-05-11","conditions":"COVID-19","enrollment":465},{"nctId":"NCT06795698","phase":"PHASE2","title":"The Effect of Prophylactic Anticoagulation on Major Bleeding Events in Hospitalized Chronic Kidney Disease and Lower Limb Fracture Patients.","status":"COMPLETED","sponsor":"Hospital Civil de Guadalajara","startDate":"2019-03-01","conditions":"Fractures, Bone, CKD Stage 4, CKD Stage 3","enrollment":61},{"nctId":"NCT03532139","phase":"PHASE2","title":"Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2018-07-25","conditions":"Ovarian Cancer","enrollment":24},{"nctId":"NCT04710732","phase":"PHASE4","title":"Individual Dose Adjustment of Low-molecular-weight-heparin by Thromodynamics Test.","status":"TERMINATED","sponsor":"Pirogov Russian National Research Medical University","startDate":"2021-03-01","conditions":"Venous Thromboembolism","enrollment":9},{"nctId":"NCT04505774","phase":"PHASE4","title":"Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE","status":"COMPLETED","sponsor":"Matthew Neal MD","startDate":"2020-09-04","conditions":"Covid19","enrollment":3591},{"nctId":"NCT04367831","phase":"PHASE4","title":"Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19","status":"COMPLETED","sponsor":"Columbia University","startDate":"2020-05-02","conditions":"COVID-19, Venous Thromboses, Arterial Thrombosis","enrollment":94},{"nctId":"NCT04427098","phase":"PHASE2","title":"Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2020-05-22","conditions":"COVID-19","enrollment":301},{"nctId":"NCT04979780","phase":"","title":"Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-07-20","conditions":"Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients","enrollment":3708},{"nctId":"NCT01717573","phase":"NA","title":"Deferred Stent Trial in STEMI","status":"COMPLETED","sponsor":"NHS National Waiting Times Centre Board","startDate":"2012-03","conditions":"ST-Elevation Myocardial Infarction","enrollment":101},{"nctId":"NCT06442267","phase":"PHASE4","title":"Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-07-30","conditions":"Respiratory Insufficiency, Circulatory Failure, Thromboembolism","enrollment":90},{"nctId":"NCT06662253","phase":"PHASE2, PHASE3","title":"Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Alexandre Tran","startDate":"2025-01","conditions":"Venous Thromboembolism (VTE), Trauma Related Injuries","enrollment":150},{"nctId":"NCT06635317","phase":"PHASE4","title":"Efficacy of Aspirin in Preventing Venous Thromboembolism","status":"COMPLETED","sponsor":"Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado","startDate":"2022-04-24","conditions":"Venous Thromboembolism (VTE), Total Joint Arthroplasty, Total Hip Arthroplasty (THA)","enrollment":60},{"nctId":"NCT00251576","phase":"PHASE3","title":"Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1999-11-01","conditions":"Acute Coronary Syndrome","enrollment":4497},{"nctId":"NCT06531525","phase":"PHASE2","title":"Effect of Low Molecular Heparin on Pregnancy Outcome With Protein S Deficiency","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-08-01","conditions":"Pregnancy Related, Protein S Deficiency","enrollment":48},{"nctId":"NCT04508855","phase":"","title":"Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)","status":"WITHDRAWN","sponsor":"AHEPA University Hospital","startDate":"2020-08-01","conditions":"Cancer, Atrial Fibrillation","enrollment":""},{"nctId":"NCT04164693","phase":"NA","title":"Efficacy and Safety of Short-term Postoperative Anticoagulant Therapy to Prevente Thrombosis in Arterovenous Fistula","status":"COMPLETED","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2019-01-01","conditions":"Thrombosis","enrollment":287},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200},{"nctId":"NCT02984384","phase":"PHASE3","title":"PREVENTion of Clot in Orthopaedic Trauma","status":"COMPLETED","sponsor":"Major Extremity Trauma Research Consortium","startDate":"2017-04-24","conditions":"Blood Clot, Trauma","enrollment":12424},{"nctId":"NCT05081375","phase":"PHASE4","title":"Pre-operative Enoxaparin in the Surgical Management of Multi-trauma Patients Undergoing Orthopedic Surgical Procedures","status":"TERMINATED","sponsor":"Valleywise Health","startDate":"2019-12-16","conditions":"Venous Thrombosis Deep (Limbs), Surgical Blood Loss","enrollment":6},{"nctId":"NCT06153394","phase":"PHASE3","title":"Prolonged Hypercoagulability Following Major Liver Resection for Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2024-06-01","conditions":"Hepatic Disease, Surgery-Complications, Hypercoagulability","enrollment":50},{"nctId":"NCT02342444","phase":"PHASE4","title":"Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)","status":"RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2014-02","conditions":"Trauma, Surgery, Deep Vein Thrombosis (DVT)","enrollment":606},{"nctId":"NCT06133803","phase":"PHASE4","title":"Lovenox With Aspirin in Thawed Blastocyst Transfer","status":"UNKNOWN","sponsor":"Fertility Center of Las Vegas","startDate":"2024-01-26","conditions":"Infertility, Female","enrollment":130},{"nctId":"NCT02604238","phase":"PHASE3","title":"Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism","status":"WITHDRAWN","sponsor":"Azienda U.S.L. 1 di Massa e Carrara","startDate":"2016-03","conditions":"Pulmonary Embolism","enrollment":""},{"nctId":"NCT03339349","phase":"PHASE2","title":"Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma","status":"COMPLETED","sponsor":"University of Utah","startDate":"2017-11-15","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolus","enrollment":80},{"nctId":"NCT04409834","phase":"PHASE4","title":"Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial","status":"COMPLETED","sponsor":"The TIMI Study Group","startDate":"2020-08-05","conditions":"COVID-19, Venous Thromboembolism, Arterial Thrombosis","enrollment":390},{"nctId":"NCT03083184","phase":"PHASE3","title":"Evaluation of the Efficacy of an inTerdialytic \"Ethanol 40% v/v - enoxapaRin 1000 U/mL\" Lock solutioN to Prevent Tunnelled Catheter Infections in Chronic Hemodialysis Patients","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2018-02-09","conditions":"Tunnelled Hemodialysis Catheter Infection","enrollment":400},{"nctId":"NCT04918524","phase":"","title":"The Clinical Features and Pregnancy Outcomes of CTD Patients","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2018-09-11","conditions":"Connective Tissue Diseases, Pregnancy Related","enrollment":126},{"nctId":"NCT05143567","phase":"NA","title":"Hemostasis and Inflammation in COVID-19 Patients With Venous and Arterial Thrombotic Complications","status":"COMPLETED","sponsor":"Ryazan State Medical University","startDate":"2021-11-01","conditions":"Venous Thromboembolism, covid19, Thrombosis","enrollment":150},{"nctId":"NCT04976465","phase":"PHASE1","title":"Treatment and Clinical Outcomes Among SLE Patients in Pregnancy","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2018-01-01","conditions":"Systemic Lupus Erythematosus, Pregnancy Related","enrollment":200},{"nctId":"NCT02303171","phase":"PHASE4","title":"Use of Warfarin After the First Trimester in Pregnant Women With APS","status":"UNKNOWN","sponsor":"Mohamed Sayed Abdelhafez","startDate":"2014-11","conditions":"Recurrent Miscarriage, Antiphospholipid Syndrome","enrollment":100},{"nctId":"NCT03296033","phase":"PHASE4","title":"Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-10-24","conditions":"Anticoagulants and Bleeding Disorders, Surgery, Regional Anesthesia Morbidity","enrollment":122},{"nctId":"NCT02744092","phase":"NA","title":"Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2016-12-13","conditions":"Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT)","enrollment":811},{"nctId":"NCT06049758","phase":"NA","title":"D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy","status":"NOT_YET_RECRUITING","sponsor":"General Committee of Teaching Hospitals and Institutes, Egypt","startDate":"2024-01-02","conditions":"Blood Loss, Intensive Care, Anastomotic Leakage","enrollment":80},{"nctId":"NCT04406389","phase":"PHASE4","title":"Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2020-10-13","conditions":"COVID-19","enrollment":14},{"nctId":"NCT04536363","phase":"PHASE2","title":"Cri Analog PG1 Effectiveness and Safety in Covid-19","status":"WITHDRAWN","sponsor":"Alonso Vera Torres","startDate":"2020-12-03","conditions":"Covid19","enrollment":""},{"nctId":"NCT00839163","phase":"PHASE2","title":"Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-03","conditions":"Venous Thrombosis, Deep Vein Thrombosis","enrollment":613},{"nctId":"NCT06025162","phase":"","title":"Evaluation of Chemical Venous Thromboembolism Prophylaxis in Trauma","status":"UNKNOWN","sponsor":"Methodist Health System","startDate":"2023-07-21","conditions":"Thromboembolism, Venous","enrollment":100},{"nctId":"NCT03083704","phase":"PHASE1","title":"A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa","status":"COMPLETED","sponsor":"Portola Pharmaceuticals","startDate":"2017-02-26","conditions":"Bleeding","enrollment":153},{"nctId":"NCT04373707","phase":"PHASE4","title":"Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2020-05-13","conditions":"COVID, Thrombosis, Pulmonary Embolism","enrollment":1000},{"nctId":"NCT01583218","phase":"PHASE3","title":"Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)","status":"COMPLETED","sponsor":"Portola Pharmaceuticals","startDate":"2012-03","conditions":"Venous Thromboembolism (VTE)","enrollment":7513},{"nctId":"NCT00375609","phase":"PHASE2","title":"Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)","status":"COMPLETED","sponsor":"Portola Pharmaceuticals","startDate":"2006-05","conditions":"Thromboembolism","enrollment":215},{"nctId":"NCT05977166","phase":"NA","title":"Hyperbaric on Pulmonary Functions in Post Covid -19 Patients.","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-03-07","conditions":"Post COVID-19 Patients","enrollment":72},{"nctId":"NCT05083455","phase":"","title":"Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-09-22","conditions":"Deep Vein Thrombosis, Pulmonary Embolus","enrollment":89215},{"nctId":"NCT04646655","phase":"PHASE3","title":"Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19","status":"COMPLETED","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2020-07-27","conditions":"Covid19, Thrombosis","enrollment":142},{"nctId":"NCT05293132","phase":"PHASE2, PHASE3","title":"Effect of Montelukast Versus Co Enzyme in Sepsis","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-02-01","conditions":"Sepsis","enrollment":90},{"nctId":"NCT05901337","phase":"NA","title":"Cupping Therapy on Immune System in Post Covid -19","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-03-07","conditions":"Covid-19 Patients","enrollment":76},{"nctId":"NCT05878899","phase":"PHASE3","title":"Postpartum Heparin Against Venous Thromboembolism: a Pilot Randomized Controlled Trial","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2022-05-03","conditions":"Venous Thromboembolism","enrollment":77}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"clexane (LMWH)","genericName":"clexane (LMWH)","companyName":"HaEmek Medical Center, Israel","companyId":"haemek-medical-center-israel","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clexane (enoxaparin) is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Thromboembolism prophylaxis in surgical patients, Treatment of deep vein thrombosis and pulmonary embolism, Acute coronary syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}